ASH 2023 | Safety and efficacy of NXC-201, an anti-BCMA CAR-T, in R/R AL amyloidosis
Vaishali Sanchorawala, MD, Boston University School of Medicine, Boston, MA, discusses findings from a Phase I/II trial (NCT04720313) investigating NXC-201, an anti-BCMA CAR-T product, in the treatment of heavily pretreated relapsed/refractory (R/R) light chain (AL) amyloidosis. The trial found a 100% hematologic response (HR) rate, with 70% being hematologic complete responses (hemCR). In terms of safety, cytokine release syndrome (CRS) was common but low-grade, and there was no neurotoxicity. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Alexion: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Prothena: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Takeda: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Abbvie: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Regeneron: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Pfizer: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding; AstraZeneca: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Research Funding.
